thiamine has been researched along with Myeloproliferative Disorders in 2 studies
thiamine(1+) : A primary alcohol that is 1,3-thiazol-3-ium substituted by (4-amino-2-methylpyrimidin-5-yl)methyl, methyl and 2-hydroxyethyl groups at positions 3, 4 and 5, respectively.
Myeloproliferative Disorders: Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gangat, N | 1 |
| Phelps, A | 1 |
| Lasho, TL | 1 |
| Finke, CM | 1 |
| Vallapureddy, R | 1 |
| Hanson, CA | 1 |
| Ketterling, RP | 1 |
| Patnaik, MM | 1 |
| Pardanani, A | 1 |
| Tefferi, A | 1 |
| Curto-García, N | 1 |
| Harrison, CN | 1 |
| McLornan, DP | 1 |
| Radia, DH | 1 |
2 other studies available for thiamine and Myeloproliferative Disorders
| Article | Year |
|---|---|
A prospective evaluation of vitamin B1 (thiamine) level in myeloproliferative neoplasms: clinical correlations and impact of JAK2 inhibitor therapy.
Topics: Antineoplastic Agents; Humans; Janus Kinase 2; Molecular Targeted Therapy; Mutation; Myeloproliferat | 2019 |
Thiamine deficiency appears uncommon in patients with Myeloproliferative Neoplasms.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Myeloproliferative Disorders; Protein Kinase | 2017 |